Stay updated with breaking news from Vifor Relypsa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Significance Statement Iron supplementation and erythropoiesis-stimulating agents (ESAs) are curr
Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients. The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia...